See how AustinPx has helped bring our clients' drug candidates to market

Case Studies

Using KinetiSolTM Technology to Improve an Abandoned Prostate Cancer Medication

In 2019, there were approximately 175,000 new cases of prostate cancer, contributing to 10% of male cancer-related fatalities. Galeterone, a novel prostate cancer candidate treatment, was discontinued after a Phase III clinical trial due to lack of efficacy. This Case Study explores how KinetiSol outperforms Spray Dried ASD and helped bring Galeterone to market.